Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Duramorph 300 Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers Results available

Opioid-Free Pain Protocol After Shoulder Arthroplasty

NCT05488847
View directory record Official record
Conditions
Shoulder Arthropathy, Shoulder Pain
Interventions
Celecoxib, Pregabalin, Tramadol, Dexamethasone, Acetaminophen, Ropivicaine, Epinephrine, Ketorolac, Tizanidine, Magnesium, Ibuprofen, Oxycodone Hydrochloride 5 Mg
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge

NCT01402375
View directory record Official record
Conditions
Analgesia After ED Discharge for Extremity Injuries
Interventions
Hydrocodone (first trial), Codeine (first trial), Oxycodone (for second trial), Codeine (for second trial), Oxycodone (third trial), Hydrocodone (third trial)
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

High Pain Intervention in Cesarean Sections

NCT01298778
View directory record Official record
Conditions
Other Chronic Postoperative Pain
Interventions
Duramorph 150, Acetaminophen, Duramorph 300
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study

NCT01229449
View directory record Official record
Conditions
Post-operative Pain
Interventions
Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen Plus®, Panadeine® Extra, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
16 Years and older
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?

NCT00492973
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic; Arthrosis
Interventions
methylprednisolone acetate, active comparator
Drug
Lead sponsor
New Lexington Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

NCT03606460
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Aurora, Colorado • Wellesley, Massachusetts • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 5, 2026, 7:34 PM EDT
Enrolling by invitation Phase 4 Interventional

Prospective Opioid-Free AIS Fusion

NCT06935331
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis (AIS)
Interventions
Opioid-Free/Opioid-Avoidant, Opioid-Containing
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
10 Years to 20 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.

NCT03996694
View directory record Official record
Conditions
Respiratory Depression
Interventions
Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg, Oxycodone 30 mg, Oxycodone 60 mg, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 5, 2026, 7:34 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Effect of Gabapentin on Postoperative Opioid Analgesic Use and Pain in Adolescents Undergoing Tonsillectomy

NCT05024825
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Gabapentin, hydrocodone, acetaminophen and ibuprofen
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
12 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 5, 2026, 7:34 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity

NCT07750639
View directory record Official record
Conditions
Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
Interventions
Naproxen, Acetaminophen, oxycodone, Gabapentin
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Not applicable Interventional

Factors Affecting the Speed of Recovery After ACL Reconstruction

NCT03770806
View directory record Official record
Conditions
Anterior Cruciate Ligament Injury, ACL Injury, ACL - Anterior Cruciate Ligament Rupture
Interventions
Femoral Nerve Block, Adductor Nerve Block, No Block
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures

NCT05076110
View directory record Official record
Conditions
Hip Arthroscopy
Interventions
Oxycodone, Ibuprofen, Gabapentin, Acetaminophen, Methocarbamol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
16 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT02688985
View directory record Official record
Conditions
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01585766
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Forms
Interventions
MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, PLACEBO-IV-SC, MEDI-551 100 MG-IV, MEDI-551 300 MG-SC, MEDI-551 600 MG-IV
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

NCT02044094
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Sep 5, 2026, 7:34 PM EDT
Active, not recruiting Phase 3 Interventional

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
CYB704, Ocrevus-EU, Ocrevus-US
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 55 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Ormond Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 5, 2026, 7:34 PM EDT
Suspended Phase 4 Interventional

Ketamine for Sedation in Severe Traumatic Brain Injury

NCT06429657
View directory record Official record
Conditions
Severe Traumatic Brain Injury, Intracranial Hypertension, Intracranial Hemorrhage, Hypertensive
Interventions
Ketamine with propofol, Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 5, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

NCT05053126
View directory record Official record
Conditions
Abuse Potential
Interventions
Pregabalin 300mg, pregabalin 450 mg, Pregabalin 300 mg with oxycodone 20 mg, pregabalin 450 mg with oxycodone 20 mg, oxycodone 20 mg, Placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 5, 2026, 7:34 PM EDT
Recruiting Phase 4 Interventional

Efficacy of Methylprednisolone for Pain Control After ACL Repair

NCT07158476
View directory record Official record
Conditions
ACL Surgery, Pain Management
Interventions
Meloxicam 15 mg, Medrol 4 MG Oral Tablet Includes Medrol Dosepak, Gabapentin 300 mg, Hydrocodone 5Mg/Acetaminophen 325Mg Tab, Ketorolac 10 Mg Oral Tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
13 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 5, 2026, 7:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
25
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 5, 2026, 7:34 PM EDT
Recruiting Phase 4 Interventional

Erector Spinae Plane Block Catheters and Intrathecal Morphine for Hepatic Resection

NCT04849455
View directory record Official record
Conditions
Hepatic Resection, Acute Pain, Anesthesia, Anesthesia, Local
Interventions
0.2% ropivacaine local anesthetic continuous erector spinae plane block, 0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block, Spinal Morphine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 5, 2026, 7:34 PM EDT
Terminated Phase 1 Interventional

Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

NCT02078089
View directory record Official record
Conditions
Cancer
Interventions
Morphine, Oxcarbazepine
Drug
Lead sponsor
Costantine Albany
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 5, 2026, 7:34 PM EDT